Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease

• Published in: Hepatology (Baltimore, Md.) Vol. 71; no. 3; pp. 808 - 819
• Main Authors: Kanwal, Fasiha, Kramer, Jennifer R., Li, Liang, Dai, Jianliang, Natarajan, Yamini, Yu, Xian, Asch, Steven M., El‐Serag, Hashem B.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01-03-2020
• Subjects: Adult; Aged; Body mass index; Carcinoma, Hepatocellular - etiology; Cirrhosis; Diabetes; Diabetes Complications - etiology; Diabetes mellitus; Dyslipidemia; Dyslipidemias - complications; Fatty liver; Female; Hepatocellular carcinoma; Hepatology; Humans; Hypertension; Hypertension - complications; Liver cancer; Liver cirrhosis; Liver Cirrhosis - etiology; Liver diseases; Liver Neoplasms - etiology; Male; Metabolism; Middle Aged; Non-alcoholic Fatty Liver Disease - complications; Obesity; Obesity - complications; Retrospective Studies; Risk
• ISSN: 0270-9139; 1527-3350
• DOI: 10.1002/hep.31014

BACKGROUND AND AIMS
Nonalcoholic fatty liver disease (NAFLD) is now the most common liver condition. Predicting its progression could help clinicians manage and potentially prevent complications. We evaluated the independent and joint effects of metabolic traits on the risk of cirrhosis and hepatocellular carcinoma (HCC) among patients with NAFLD.
APPROACH AND RESULTS
We assembled a retrospective cohort of patients with NAFLD diagnosed at 130 facilities in the Veterans Administration between January 1, 2004, and December 31, 2008, with follow‐up through December 31, 2015. We performed competing risk‐adjusted cause‐specific Cox models to evaluate the effects of metabolic traits (diabetes, hypertension, dyslipidemia, obesity) as additive or combined indicators on time to develop cirrhosis or HCC or a composite endpoint of both. Of the 271,906 patients, 22,794 developed cirrhosis, and 253 developed HCC during a mean of 9 years follow‐up. At baseline, the mean body mass index was 31.6 (SD, 5.6), 28.7% had diabetes, 70.3% had hypertension, and 62.3% had dyslipidemia with substantial overlap among these traits. The risk of progression was the lowest in patients with only one or no metabolic trait. There was a stepwise increase in risk with each additional metabolic trait. Compared with patients with no metabolic trait, patients with both hypertension and dyslipidemia had 1.8‐fold higher risk of progression to cirrhosis/HCC (hazard ratio [HR] = 1.8, 95% confidence interval [CI] = 1.59‐2.06); the risk was 2.6‐fold higher in patients with diabetes, obesity, dyslipidemia, and hypertension (HR = 2.6, 95% CI = 2.3‐2.9). These associations were stronger for HCC. Diabetes had the strongest association with HCC in this cohort.
CONCLUSIONS
Each additional metabolic trait increased the risk of cirrhosis and HCC in patients with NAFLD. Diabetes conferred the highest risk of progression to HCC. Patients with diabetes and coexisting hypertension and obesity may be important targets for secondary prevention.